Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 98.90 TWD
Change Today -0.30 / -0.30%
Volume 3.0M
As of 2:31 AM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

tty biopharm co ltd (4105) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/23/15 - 101.50
52 Week Low
10/27/14 - 49.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TTY BIOPHARM CO LTD (4105)

Related News

No related news articles were found.

tty biopharm co ltd (4105) Related Businessweek News

No Related Businessweek News Found

tty biopharm co ltd (4105) Details

TTY Biopharm Company Limited engages in the development and marketing of oncology and anti-infective generic drugs worldwide. It also offers healthcare product for cardiovascular diseases, hepatic and renal diseases, and peptic ulcers, as well as for drug allergies. The company was founded in 1960 and is headquartered in Taipei City, Taiwan.

Founded in 1960

tty biopharm co ltd (4105) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

tty biopharm co ltd (4105) Key Developments

PharmaMar Enters into Licensing Agreement with TTY Biopharm Company

PharmaMar S.A. has entered into an exclusive license and commercialization agreement with TTY Biopharm Company Limited to market and distribute the drug candidate APLIDIN (R) (plitidepsin) in Taiwan. PharmaMar and TTY Biopharm are Biopharmaceutical Companies based in Spain and Taiwan, respectively. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (R) (plitidepsin). PharmaMar will retain exclusive production rights and will supply the finished product to TTY Biopharm for commercial use.

TTY Biopharm Company Limited, Annual General Meeting, Jun 16, 2015

TTY Biopharm Company Limited, Annual General Meeting, Jun 16, 2015.

TTY Biopharm Is Mulling Acquiring Its Vietnamese Partner

TTY Biopharm Company Limited (GTSM:4105) is mulling acquiring its Vietnamese partner as TTY Biopharm eyes overseas mergers as a way to boost its sales next year. TTY Biopharm is considering the acquisition because Vietnam is the country with the highest economic growth in Southeast Asia and its local partner has a strong marketing team, TTY Chairman Clark Hsiao told reporters on December 16, 2014. The potential acquisition is part of TTY’s strategy to strengthen its retail networks in South Korea, Vietnam and the Philippines next year and increase sales, Hsiao said.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4105:TT 98.90 TWD -0.30

4105 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4105.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4105 Industry Range
Price/Earnings 23.6x
Price/Sales 7.9x
Price/Book 6.0x
Price/Cash Flow 23.5x
TEV/Sales 6.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TTY BIOPHARM CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at